TABLE 3.
Individual patient and tumor characteristics
| Subject | Age | Gender | Diagnosis | Disease presentation | PD‐L1 expression a | NGS somatic variants b | ||
|---|---|---|---|---|---|---|---|---|
| TP53 | KRAS | Other | ||||||
| 101‐301 | 64 | M | ADC | Lung, LN | <1% | WT | G12C | |
| 101‐302 | 54 | M | ADC | LN, Adrenal | >50% | R158L | WT | |
| 101‐303 | 51 | F | ADC | Lung | N/A | N/A | N/A | |
| 101‐304 | 60 | M | ADC | Lung | 3% | G245V | G12C | |
| 101‐305 | 45 | M | Large cell | Lung, LN, Peritoneal | <1% | G334V | WT | |
| 101‐306 | 58 | M | ADC | Lung, LN | N/A | WT | WT | |
| 101‐307 | 56 | F | ADC | Lung, LN, Bone | <1% | WT | G12D | |
| 101‐308 | 68 | M | ADC | LN, Bone, Muscle | <1% | R248Q | WT | ATM |
| 101‐309 | 63 | M | ADC | Lung, LN | <1% | N/A | N/A | |
| 101‐310 | 63 | F | ADC | LN, Bone | 5%–10% | G199V | WT | BRAF (V600E) |
| 101‐311 | 39 | M | ADC | Lung, LN, Liver | <1% | N/A | N/A | |
| 101‐312 | 62 | M | ADC | Lung, Adrenal, Bone | <1% | WT | Q61H | |
| 101‐313 | 60 | F | ADC | Lung, LN, Pleural, Pericardial Bone | 80%–90% | E285V | G13C | |
| 101‐314 | 50 | M | ADC | Lung, LN, Liver, Pleural | <1% | WT | WT | |
| 101‐315 | 65 | M | Giant cell | Lung, LN, Adrenal | 100% | Y126D | WT | |
| 101‐316 | 60 | F | ADC | Lung, LN, Adrenal | <1% | WT | G12D | APC |
| 101‐317 | 59 | F | ADC | Lung, LN, Liver, Bone | <1% | G244R | WT | RB1; ERBB2 |
| 101‐318 | 53 | M | ADC | Lung | 10%–20% | G245V | WT | CDKN2A; HRAS |
| 101‐319 | 70 | M | ADC | Lung, LN | 60%–70% | R248L | WT | |
| 101‐320 | 78 | M | ADC | Lung, LN | 60%–70% | R249T | WT | JAK3 P132T |
| 103‐301 | 61 | F | ADC | N/A | N/A | N/A | N/A | |
Abbreviations: ADC, adenocarcinoma; F, female; M, male; N/A, not available; NGS, next‐generation sequencing; PD‐L1, programmed cell death‐ligand 1.
a
PD‐L1 expression assessed using the 22C3 immunohistochemistry assay.
b
Somatic variants detected using Ion AmpliSeqTM Cancer Hotspot Panel v2 analysis of tumor DNA.